Reducing Heavy Drinking to Optimize HIV/AIDS Treatment and Prevention
Status:
Completed
Trial end date:
2017-08-01
Target enrollment:
Participant gender:
Summary
This is a double-blind placebo-controlled study to evaluate the effect of Naltrexone (NTX)
and counseling on highly active antiretroviral treatment (HAART) medication adherence in a
cohort of HIV-infected patients who report heavy drinking, or meet criteria for alcohol abuse
and/or dependence, and inadequate (< 95%) HAART adherence. All patients will receive a
behavioral intervention, termed Medical Management/Medication Coaching or MM/MC. MM/MC
incorporates the behavioral platform Medical Management (MM) from the National Institute on
Alcohol Abuse and Alcoholism (NIAAA)-funded COMBINE Study to reduce heavy alcohol use with
Medication Coaching (MC), a manualized treatment designed to improve HAART medication
adherence in HIV-infected patients with substance use disorders.
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Yale University
Collaborator:
National Institute on Alcohol Abuse and Alcoholism (NIAAA)